S'abonner

Untargeted serum metabolomic analysis reveals a role for purinergic signaling in FPIES - 03/03/23

Doi : 10.1016/j.jaci.2022.09.035 
Daniel Lozano-Ojalvo, PhD a, b, c, Xin Chen, PhD c, d, David Dunkin, MD c, d, Charuta Agashe, MS a, b, Mary Grace Baker, MD b, J. Andrew Bird, MD e, Elena Molina, PhD f, Anna Nowak-Wegrzyn, MD, PhD g, h, , M. Cecilia Berin, PhD a, b, c,
a Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York 
b Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York 
c Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York 
d Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai, New York 
e Department of Pediatrics, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas 
f Instituto de Investigación en Ciencias de la Alimentación CIAL, Madrid 
g Department of Pediatrics, New York University Grossman School of Medicine, Hassenfeld Children’s Hospital, New York 
h Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland 

Corresponding author: M. Cecilia Berin, PhD, Mount Sinai School of Medicine Pediatrics, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1198, New York, NY 10029.Mount Sinai School of Medicine PediatricsMount Sinai School of MedicineOne Gustave L. Levy PlaceBox 1198New YorkNY10029

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Abstract

Background

Food protein–induced enterocolitis syndrome (FPIES) is a non–IgE-mediated food allergy with a typical onset in infancy. Its symptoms are distinct from those of IgE-mediated food allergies and include severe repetitive vomiting, lethargy, and pallor. FPIES reactions are associated with TH17 cytokines and a systemic innate immune activation; however, the link between immune activation and symptoms is poorly understood.

Objective

Our aim was to use an untargeted metabolomics approach to identify novel pathways associated with FPIES reactions.

Methods

Serum samples were obtained before, during, and after oral food challenge (OFC) (10 subjects with FPIES and 10 asymptomatic subjects), and they were analyzed by untargeted metabolomics. Two-way ANOVA with false discovery rate adjustment was used for analysis of metabolites. Stomach and duodenal biopsy specimens from non-FPIES donors were stimulated with adenosine in vitro and serotonin measured by immunoassay.

Results

The levels of a total of 34 metabolites, including inosine and urate of the purine signaling pathway, were increased during OFCs performed on the patients with symptomatic FPIES compared with the levels found for asymptomatic subjects. Expression of the purine receptors P2RX7 and P2RY10 and the ectonucleotidase CD73 in peripheral blood was significantly reduced after OFC of the patients with FPIES. The level of the serotonin metabolite 5-hydroxyindoleacetate was significantly elevated after reaction. Adenosine stimulation of gastric and duodenal biopsy specimens from FPIES-free donors induced a significant release of serotonin, suggesting a link between purinergic pathway activation and serotonin release.

Conclusions

Activation of the purinergic pathway during FPIES reactions provides a possible mechanism connecting inflammation and vomiting by triggering serotonin release from gastric and duodenal mucosa.

Le texte complet de cet article est disponible en PDF.

Key words : FPIES, metabolomics, purine metabolism, adenosine, serotonin, ATP

Abbreviations used : EC, FPIES, OFC, Rs


Plan


 Supported in part by the Katy and Kyle Miller Family Fund and the National Institutes of Health (grants AI136053 and AI151707).
 Disclosure of potential conflict of interest: M. G. was supported in part by the Louis and Rachel Rudin Foundation. J. A. Bird reports research support from the National Institutes of Health–National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Aimmune, DBV Technologies, FARE, and Astellas; consulting for Allergy Therapeutics, Before Brands, AllerGenis, DBV Technologies, HAL Allergy, and Novartis; and medical advisory board participation for the International Food ProteinInduced Enterocolitis Syndrome (FPIES) Association. A. Nowak-Wegrzyn reports research support from the NIAID, DBV Technologies, Astellas Pharma, Danone and Nestle, as well as consultancy fees from Regeneron and Gerber Institute; in addition, she serves as the deputy editor for the Annals of Allergy, Asthma and Immunology and the chair of the medical advisory board of the International FPIES Association. M. C. Berin reports funding to her institution from the NIAID. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 151 - N° 3

P. 797-802 - mars 2023 Retour au numéro
Article précédent Article précédent
  • Human MD2 deficiency—an inborn error of immunity with pleiotropic features
  • Yue Li, Ziqi Yu, Madlin Schenk, Irena Lagovsky, David Illig, Christoph Walz, Meino Rohlfs, Raffaele Conca, Aleixo M. Muise, Scott B. Snapper, Holm H. Uhlig, Ben Zion Garty, Christoph Klein, Daniel Kotlarz
| Article suivant Article suivant
  • Accurate phenotyping of cross-reactive hypersensitivity is essential to shed light on the underlying mechanisms in NSAID-induced urticaria/angioedema
  • José Antonio Cornejo-García, Rafael Núñez, María J. Torres, Inmaculada Doña

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.